FDA Adverse Event Monitoring "Flaws" Highlighted In GAO Transition Report
Executive Summary
Improving the monitoring of drug adverse events is one of FDA's main challenges, a General Accounting Office transition report on HHS indicates.
You may also be interested in...
Senate HHS Approps Chair Harkin Looking At FDA Rules On Women In Trials
The representation of women in clinical trials will be a likely hearing topic for the Senate Appropriations/Labor, HHS & Education Subcommittee under incoming Chairman Harkin (D-Iowa).
Senate HHS Approps Chair Harkin Looking At FDA Rules On Women In Trials
The representation of women in clinical trials will be a likely hearing topic for the Senate Appropriations/Labor, HHS & Education Subcommittee under incoming Chairman Harkin (D-Iowa).
Recent Drug Withdrawals Had Greater Health Risks For Women - GAO Report
Eight of 10 prescription drugs withdrawn from the market since Jan. 1, 1997 presented more significant health risks for women than men, a General Accounting Office report finds.